Towards Healthcare
Viral Vector-Based Cell & Gene Therapy CDMO Market to Surge USD 497.7 Mn by 2034

Viral Vector-Based Cell & Gene Therapy CDMO Market Trends Ahead

According to market projections, the viral vector-based cell & gene therapy CDMO sector is expected to grow from USD 142.77 million in 2024 to USD 497.7 million by 2034, reflecting a CAGR of 13.44%. The key benefits of collaborating with a viral vector CDMO including therapeutic development and clinical trials drive the expansion of these organizations. North America dominated the market in 2024 driven by the largest expansion of clinical programs, approved CGTs, and CDMO capacity. 

  • Insight Code: 6104
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The viral vector-based cell & gene therapy CDMO market stands at USD 162 million in 2025 and is expected to reach USD 497.7 million by 2034, growing at a CAGR of 13.44% from 2024 to 2034.

North America is currently leading the viral vector-based cell & gene therapy CDMO market share 46% due to favorable regulatory environment, increased investments, and funding.

Some key players include Lonza, Catalent, Samsung Biologics, Oxford Biomedica, etc.

Key trends include high-demand vector platforms, downstream process improvements, expansion of suspension-based systems, etc.